RCM
BDTX icon

RB Capital Management’s Black Diamond Therapeutics BDTX Stock Holding History

RB Capital Management’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$74.5K Hold
35,000
– – 0.02% 184
2025
Q4 		$85K Buy
+35,000
New +$124K 0.02% 194

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

RB Capital Management's BDTX Position: Q1 2026 in Review

RB Capital Management held its Black Diamond Therapeutics (BDTX) position steady in Q1 2026 at 35,000 shares worth $74.5K. The position accounts for 0.02% of the portfolio, ranked #184.

RB Capital Management first reported a position in BDTX in Q4 2025 and has held it in 2 quarters since. The position peaked at $85K in Q4 2025. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

  • RB Capital Management held 35,000 shares of Black Diamond Therapeutics worth $74.5K as of Q1 2026.
  • RB Capital Management left its Black Diamond Therapeutics share count unchanged in Q1 2026.
  • Black Diamond Therapeutics made up 0.02% of RB Capital Management's portfolio in Q1 2026, its #184 holding.
  • RB Capital Management first reported a position in Black Diamond Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • RB Capital Management's Black Diamond Therapeutics position peaked at $85K in Q4 2025.
  • 104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on RB Capital Management's 13F filing for Q1 2026, filed 15 May 2026.